Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
Yukinori Ozaki,
Junji Tsurutani,
Toru Mukohara,
Tsutomu Iwasa,
Masato Takahashi,
Yuko Tanabe,
Hidetaka Kawabata,
Norikazu Masuda,
Manabu Futamura,
Hironobu Minami,
Koji Matsumoto,
Kenichi Yoshimura,
Shigehisa Kitano,
Toshimi Takano
Affiliations
Yukinori Ozaki
Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Corresponding author at: Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Junji Tsurutani
Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan
Toru Mukohara
Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Tsutomu Iwasa
Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan
Masato Takahashi
Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan
Yuko Tanabe
Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
Hidetaka Kawabata
Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan
Norikazu Masuda
Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan
Manabu Futamura
Breast Surgery, Gifu University Hospital, Gifu, Japan
Hironobu Minami
Medical Oncology/Hematology, Internal Medicine, School of Medicine, Kobe University, Hyogo, Japan
Koji Matsumoto
Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan
Kenichi Yoshimura
Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan
Shigehisa Kitano
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Toshimi Takano
Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were collected. The serum samples were used to measure the concentrations of cytokines. Progression-free survival (PFS), overall survival (OS), and response were analyzed in association with the biomarker data using the Kaplan–Meier method and log-rank tests. Fifty patients were included in the biomarker analysis. Programmed death-ligand 1 (PD-L1) expression on tumor cells and immune cells were evaluated in tumor tissue samples using a Dako 28-8 immunohistochemistry assay and using a VENTANA SP142 immunohistochemistry assay. PD-L1 positive rates using anti-PD-L1 antibodies 28-8 (Combined positive score [CPS] ≥1) and SP142 (Immune cells [IC] ≥1) were 15% and 17%, respectively. The PFS and OS were not significantly different in the subgroups by PD-L1 expression. The median pretreatment vascular endothelial growth factor (VEGF)-A concentration was 116.1 pg/ml (range 0–740.23 pg/ml) on day 1 and decreased to <37 pg/ml on day 8 of cycle 1 in all patients. Subtypes (hormone receptor-positive HER2-negative or triple negative breast cancer), stage (recurrent or de novo stage IV) and liver metastasis (yes or no) were not significantly different between patients in VEGF-A high and VEGF-A low groups. PFS in the VEGF-A high group was similar to that in the VEGF-A low group.
